Wed, 20 May 2015
Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C someday. Motley Fool's Michael Douglass and Todd Campbell dig into the details of this deal to see if Gilead Sciences investors should worry. |